A biomarker test to measure progression for Parkinson's Disease is available in the US before 2029
Santé et médecineOne-Off2aManifold MarketsSans KYCDonnées de résolution vérifiéesAssez bien calibréPrévision communautaire actuelleOui 71.7%
Prévisionnistes
6
Type de question
binary
Méthodologie
Play-money forecasting platform
Type de source
Prévision
Données du marché
Mis à jour il y a 16 heures
Obsolète25 avr. 23, 16:13 UTC2 janv. 29, 06:59 UTC
Tendances
Règles
There will be a test of a biomarker which meaningfully correlates with parkinson's progression for at least a signficant subset (>10% of those diagnosed clinically) of people with Parkinson's disease in the US before 2029
- examples: Patient has classic non-genetic PD from a clinical diagnosis based on symptoms (rigidity, etc.).
- There will be a test which they can take which shows the severity of the disease, and which when given repeatedly can be used to measure how much or less the disease has progressed
